Prospects for a dengue virus vaccine

被引：444

作者：

Whitehead, Stephen S.

Blaney, Joseph E.

Durbin, Anna P.

Murphy, Brian R.

机构：

[1] NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA

[2] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Immunizat Res, Dept Int Hlth, Baltimore, MD 21205 USA

来源：

NATURE REVIEWS MICROBIOLOGY | 2007年 / 5卷 / 07期

关键词：

D O I：

10.1038/nrmicro1690

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The number of cases of severe dengue disease continues to grow in endemic areas of southeast Asia, Central and South America, and other subtropical regions. Children bear the greatest burden of disease, and the development of an effective vaccine remains a global public health priority. A tetravalent vaccine is urgently needed and must be effective against all four dengue virus serotypes, be cost-effective and provide long-term protection. In this Review we discuss the unique immunological concerns in dengue virus vaccine development and the current prospects for the development of an acceptable vaccine, a goal that is likely to be reached in the near future.

引用

收藏

页码：518 / 528

页数：11

相关论文

共 119 条

[1] Structures of immature flavivirus particles [J].

Zhang, Y ;

Corver, J ;

Chipman, PR ;

Zhang, W ;

Pletnev, SV ;

Sedlak, D ;

Baker, TS ;

Strauss, JH ;

Kuhn, RJ ;

Rossmann, MG .

EMBO JOURNAL, 2003, 22 (11) :2604-2613

[2] Vascular leakage in severe dengue virus infections: A potential role for the nonstructural viral protein NS1 and complement [J].

Avirutnan, P ;

Punyadee, N ;

Noisakran, S ;

Komoltri, C ;

Thiemmeca, S ;

Auethavornanan, K ;

Jairungsri, A ;

Kanlaya, R ;

Tangthawornchaikul, N ;

Puttikhunt, C ;

Pattanakitsakul, SN ;

Yenchitsomanus, PT ;

Mongkolsapaya, J ;

Kasinrerk, W ;

Sittisombut, N ;

Husmann, M ;

Blettner, M ;

Vasanawathana, S ;

Bhakdi, S ;

Malasit, P .

JOURNAL OF INFECTIOUS DISEASES, 2006, 193 (08) :1078-1088

[3] Development of a live attenuated dengue virus vaccine using reverse genetics [J].

Blaney, JE ;

Durbin, AP ;

Murphy, BR ;

Whitehead, SS .

VIRAL IMMUNOLOGY, 2006, 19 (01) :10-32

[4] Genetically modified, live attenuated dengue virus type 3 vaccine candidates [J].

Blaney, JE ;

Hanson, CT ;

Firestone, CY ;

Hanley, KA ;

Murphy, BR ;

Whitehead, SS .

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2004, 71 (06) :811-821

[5] Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2 [J].

Blaney, JE ;

Hanson, CT ;

Hanley, KA ;

Murphy, BR ;

Whitehead, SS .

BMC INFECTIOUS DISEASES, 2004, 4 (1)

[6] Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys [J].

Blaney, JE ;

Matro, JM ;

Murphy, BR ;

Whitehead, SS .

JOURNAL OF VIROLOGY, 2005, 79 (09) :5516-5528

[7] MICE IMMUNIZED WITH RECOMBINANT VACCINIA VIRUS EXPRESSING DENGUE-4 VIRUS STRUCTURAL PROTEINS WITH OR WITHOUT NONSTRUCTURAL PROTEIN-NS1 ARE PROTECTED AGAINST FATAL DENGUE VIRUS ENCEPHALITIS [J].

BRAY, M ;

ZHAO, BT ;

MARKOFF, L ;

ECKELS, KH ;

CHANOCK, RM ;

LAI, CJ .

JOURNAL OF VIROLOGY, 1989, 63 (06) :2853-2856

[8] DENGUE VIRUS-SPECIFIC CROSS-REACTIVE CD8+ HUMAN CYTO-TOXIC T-LYMPHOCYTES [J].

BUKOWSKI, JF ;

KURANE, I ;

LAI, CJ ;

BRAY, M ;

FALGOUT, B ;

ENNIS, FA .

JOURNAL OF VIROLOGY, 1989, 63 (12) :5086-5091

[9] A PROSPECTIVE-STUDY OF DENGUE INFECTIONS IN BANGKOK [J].

BURKE, DS ;

NISALAK, A ;

JOHNSON, DE ;

SCOTT, RM .

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1988, 38 (01) :172-180

[10] Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5′ noncoding region and nonstructural proteins 1 and 3 [J].

Butrapet, S ;

Huang, CYH ;

Pierro, DJ ;

Bhamarapravati, N ;

Gubler, DJ ;

Kinney, RM .

JOURNAL OF VIROLOGY, 2000, 74 (07) :3011-3019

← 1 2 3 4 5 6 7 8 9 10 →